10-K: Polomar Health Services Navigates Strategic Shift with Pharmacy Focus in Annual Report

Polomar Health Services' annual report highlights a strategic shift towards specialty pharmacy operations following a merger, while addressing financial challenges and future growth plans.

Summary

• Polomar Health Services, formerly Trustfeed Corp., has shifted its focus to specialty pharmacy operations, particularly compounding, following a merger with Polomar Specialty Pharmacy, LLC.
• The company is licensed to dispense compounded medications in 28 states and aims to expand to a majority of U.S. states by the end of 2025, with plans to pursue a drug export permit.
• Polomar owns SlimRx, an online platform for weight loss medications, and plans to launch PoloMeds in Q2 2025 for diabetes and erectile dysfunction medications, as well as dermatological formulations.
• The company's business model includes providing prescription fulfillment services for third-party telehealth platforms.
• A stock purchase agreement in December 2023 resulted in a change of control, with CWR 1, LLC acquiring a majority stake and new management suspending the pre-existing business operations.
• A merger agreement in September 2024 completed the acquisition of Polomar Specialty Pharmacy, LLC, with Polomar's historical financial statements being substituted for Trustfeed's.
• The company executed a license agreement with Pinata Holdings, Inc. for intellectual property rights related to the delivery of products containing metformin, eletriptan, semaglutide, liraglutide, and sildenafil.
• As of December 31, 2024, the company had total current assets of approximately $76,813 and total current liabilities of $1,337,778, resulting in a working capital deficit of $1,260,965.
• The company recorded a net loss of $1,341,333 for the fiscal year ended December 31, 2024, and has an accumulated deficit of $2,911,163.
• Management plans to raise additional capital and invest in sales and marketing to increase distribution and demand for its platform database.
• The company acknowledges substantial doubt about its ability to continue as a going concern without generating sufficient revenues or raising additional capital.

Sentiment

Score: 3

Explanation: The document presents a concerning financial picture with significant losses, a working capital deficit, and doubts about the company's ability to continue as a going concern. While there are positive aspects like the focus on specialty pharmacy and potential for growth, the overall sentiment is negative due to the financial challenges.

Positives

• The company has a license to operate a compounding pharmacy in Florida and is licensed to dispense medications in 28 states.
• The company owns SlimRx, an online platform for weight loss medications, and plans to launch PoloMeds for diabetes and erectile dysfunction medications.
• The company has a license agreement with Pinata Holdings, Inc. for intellectual property rights related to drug delivery.
• The company is actively seeking approval and authorization in other states and expects to be able to provide prescription medications in a majority of U.S. states by the end of 2025.

Negatives

• The company has a working capital deficit of $1,260,965 as of December 31, 2024.
• The company recorded a net loss of $1,341,333 for the fiscal year ended December 31, 2024.
• The company has an accumulated deficit of $2,911,163 as of December 31, 2024.
• Management expresses substantial doubt about the company's ability to continue as a going concern without additional funding.
• The company is subject to significant related party short term debt and other current liabilities, which we may be unable to repay.

Risks

• The company is a development stage company with a limited operating history, making it difficult to evaluate the business and investment.
• The company has not established any material and recurring revenues or operations that will provide financial stability in the long term.
• The company may never become profitable.
• If the company fails to obtain additional financing, it may be unable to complete the roll-out of its business and services.
• The company is subject to significant related party short term debt and other current liabilities, which it may be unable to repay.
• There is a limited trading market for the company's common stock, which could make it difficult to liquidate an investment in a timely manner.
• The company's common stock is subject to the penny stock rules of the SEC, which makes transactions in the stock cumbersome and may reduce the value of an investment in the stock.
• The company intends to issue more shares to raise capital, which will result in substantial dilution.
• Failure to establish and maintain an effective system of internal controls could result in material misstatements of the company's financial statements or cause the company to fail to meet its reporting obligations or fail to prevent fraud.

Future Outlook

Management plans to raise additional capital and invest its working capital resources in sales and marketing in order to increase the distribution and demand for its platform database. However, there is no guarantee the Company will generate sufficient revenues or raise capital to continue operations.

Management Comments

• Management evaluated all relevant conditions and events that are reasonably known or reasonably knowable, in the aggregate, as of the date the consolidated financial statements are issued and determined that substantial doubt exists about the Company's ability to continue as a going concern.
• The Company's ability to continue as a going concern is dependent on the Company's ability to generate revenues and raise capital.

Industry Context

The company is operating in the competitive specialty pharmacy and telehealth sectors, focusing on compounded medications and prescription fulfillment services. The success of Polomar Health Services will depend on its ability to differentiate itself, navigate regulatory requirements, and secure market share in these evolving industries.

Comparison to Industry Standards

• Given the limited financial details and the company's early stage, it's challenging to provide a detailed comparison to industry standards.
• Comparable companies in the specialty pharmacy space include firms like Diplomat Pharmacy (now OptumRx, part of UnitedHealth Group) and Accredo (Express Scripts), but these are much larger and more established.
• In the telehealth space, companies like Teladoc Health and Amwell are key players, but Polomar's focus on prescription fulfillment provides a different angle.
• Without specific revenue and growth metrics, it's difficult to benchmark Polomar against industry averages for profitability, customer acquisition cost, or market penetration.

Management Changes

Corporate Governance

Legal Proceedings

• From time to time, the company may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business.

Related Party Transactions

• The company has entered into related party promissory notes with Reprise Management, Inc. and CWR 1, LLC.
• The company has made advances to a shareholder and a company commonly controlled by a director of the company.

Stakeholder Impact

• Shareholders face potential dilution from future stock issuances.
• Employees may be affected by the company's financial instability and potential need to scale back operations.
• Customers may benefit from the company's expanded medication dispensing capabilities and new product offerings.
• Suppliers and creditors face increased risk due to the company's financial challenges.

Next Steps

• Raise additional capital to fund operations and expansion.
• Increase distribution and demand for the company's platform database.
• Launch PoloMeds platform in Q2 2025.
• Seek approval and authorization to dispense medications in additional states.
• Consider applying for a drug export permit in Q3 2025.

Key Dates

Keywords

specialty pharmacy, compounding, pharmaceuticals, merger, financial performance, Polomar Health Services, SlimRx, PoloMeds, telehealth, drug delivery